Pharmacy

U.S pharmaceutical industry currently stands at $450 Billion, with six among the top 10 companies around the world, belonging to the country based on pure pharmaceutical revenue. Four of the […]

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt. […]

Takeda Pharmaceutical Co. on Tuesday reached an agreement to buy Shire PLC, capping a monthslong battle for control of the European drugmaker and marking the largest-ever overseas acquisition by a […]

Novartis’s third-quarter core net income rose 4 percent at constant currencies, beating analyst expectations, as the Swiss drugmaker said it made “significant progress” in preparing its Alcon eyecare unit for a possible spinoff by the first half of 2019.

For fiscal 2017, the company continues to expects net sales to be broadly in line with prior year and core operating income to be broadly in line or decline low single digit, both at constant currency rates.

Just days after Gilead and its new subsidiary Kite won a groundbreaking FDA approval for their CAR-T therapy Yescarta for B-cell lymphomas, Lausanne, ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, announced that it has raised $200 million through a private placement. The financing was oversubscribed and supported by both existing and new investors, including Auven Therapeutics, Redmile, the Wild Family Office and AstraZeneca.

Novartis announced that its Chief Executive Officer Joseph Jimenez has informed the board of directors of his desire to step down in 2018. The company’s board has appointed Vasant Narasimhan, its Global Head of Drug Development and Chief Medical Officer, to the position of CEO, effective February 1, 2018. Narasimhan is a member of the Executive Committee.

Gilead Sciences Inc agreed to buy Kite Pharma Inc in a $11.9 billion deal on Monday, as it looks to fuel growth with an emerging class of cancer immunotherapies that are expected to generate billions.

Gilead will pay $180 per share in an all-cash deal, representing a 29.4 percent premium over Kite’s Friday close. Kite’s shares were trading up at $178.15 before the bell.

Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite. The trial will test the efficacy of KAF156 in combination with a new, improved formulation of the existing antimalarial lumefantrine. The first trial center is operational in Mali and will be followed by sixteen additional centers across a total of nine countries in Africa and Asia over the next few months.